BRCA Gene Testing: What Your Results Mean and What to Do Next

Receiving a BRCA genetic test result — whether positive, negative, or ambiguous — is one of the most significant pieces of medical information a person can encounter. The BRCA1 and BRCA2 genes are tumour suppressors: when they function normally, they orchestrate the repair of double-strand DNA breaks, one of the most dangerous forms of genetic damage a cell can sustain. When a pathogenic variant disrupts that repair machinery, the lifetime risk of breast, ovarian, and several other cancers rises sharply. Understanding exactly what your result means is the essential first step before any clinical decision is made.

This guide walks through the biology of BRCA variants, how to interpret each result category, the evidence-based management options available at every stage, and how to navigate the healthcare system — including family testing, insurance considerations, and the role of AI-assisted genomic interpretation — so that you can move from uncertainty to an actionable, personalised plan.

The Biology Behind BRCA1 and BRCA2

What These Genes Actually Do

BRCA1 and BRCA2 encode large proteins that are central to homologous recombination (HR), the cell's highest-fidelity method of repairing broken DNA strands. When ultraviolet radiation, oxidative stress, or replication errors snap both strands of the double helix, HR uses the intact sister chromatid as a template to reconstruct the sequence perfectly. BRCA1 acts as a scaffold and signalling hub that recognises the break, recruits repair proteins, and decides which repair pathway to deploy. BRCA2 loads the RAD51 recombinase onto the broken strand, enabling it to search for and invade the homologous template.

When one copy of BRCA1 or BRCA2 carries a pathogenic variant, the cell can still function — the second, normal copy compensates. Cancer emerges when somatic mutation silences that second copy in a tissue cell, leaving the cell with no functioning HR machinery. The resulting genomic instability accelerates the accumulation of further mutations, driving malignant transformation. This two-hit model explains why BRCA variants are inherited with high penetrance but do not cause cancer in every cell of every carrier's body.

Lifetime Risk Numbers in Context

Large prospective cohort studies place the cumulative risk of breast cancer by age 80 at approximately 72% for BRCA1 carriers and 69% for BRCA2 carriers, compared with around 12% in the general population. For ovarian cancer, BRCA1 carriers face roughly a 44% lifetime risk and BRCA2 carriers around 17%, versus about 1.2% in the general population. These figures are averages across all pathogenic variants; specific variants and family history modifiers can shift individual risk meaningfully above or below these estimates. This is why personalised risk modelling rather than population averages should guide clinical decision-making.

Interpreting Your Result: Four Categories

Pathogenic or Likely Pathogenic

A result classified as pathogenic (P) or likely pathogenic (LP) means the laboratory has identified a variant with strong evidence of harm to gene function. These two categories are clinically treated identically. A P/LP result triggers active risk management: enhanced surveillance, consideration of chemoprevention, and discussion of risk-reduction surgery. It also has direct implications for immediate family members, each of whom has a 50% probability of carrying the same variant.

Variant of Uncertain Significance

A variant of uncertain significance (VUS) is neither a positive nor a negative result. The laboratory has found a sequence change, but the available functional, epidemiological, and computational evidence does not yet permit a confident classification. Critically, a VUS should not be used to justify prophylactic mastectomy or oophorectomy. Clinical management should follow general population or family-history-based guidelines until the VUS is reclassified. Laboratories are obligated to contact you if the classification changes, but it is worth actively following up every one to two years, as reclassification rates are substantial — studies suggest that around 8–10% of VUS findings are reclassified within five years, the majority to benign or likely benign.

Benign or Likely Benign

Variants classified as benign (B) or likely benign (LB) have sufficient evidence to conclude they do not meaningfully increase cancer risk. These findings require no clinical action beyond standard care and screening for your age and general risk profile. They are often not even reported by laboratories, as they are considered non-actionable. If a benign variant appears on your report alongside other findings, it should not influence management decisions.

Risk-Reduction Strategies for Pathogenic Variant Carriers

Enhanced Surveillance

For carriers who choose surveillance rather than immediate surgery, international guidelines recommend annual breast MRI beginning at age 25 for BRCA1 carriers and age 30 for BRCA2 carriers, alternating with annual mammography to provide six-monthly imaging. MRI is preferred because it has substantially higher sensitivity (approximately 75–80%) than mammography alone (approximately 30–40%) in dense breast tissue, which is common in younger carriers. For ovarian cancer surveillance, transvaginal ultrasound and CA-125 testing every six months are sometimes offered, but the evidence that this surveillance reduces ovarian cancer mortality is weak, which is why surgical prevention is discussed earlier and more seriously for ovarian risk than for breast risk.

This connects directly to the broader evolution of liquid biopsy technologies, which are beginning to offer circulating tumour DNA detection sensitive enough to identify early-stage ovarian cancer — a historically difficult malignancy to detect before it has spread. As these assays mature into clinical practice, they may substantially alter the surveillance calculus for BRCA carriers.

Chemoprevention

Selective oestrogen receptor modulators (SERMs) such as tamoxifen and raloxifene, and aromatase inhibitors (AIs) such as anastrozole and exemestane, can reduce the risk of hormone receptor-positive breast cancer by approximately 50% in high-risk premenopausal and postmenopausal women respectively. However, because BRCA1-associated tumours are predominantly ER-negative, chemoprevention offers less protection for BRCA1 carriers than for BRCA2 carriers and the general high-risk population. The decision to use chemoprevention must weigh side-effect profiles — tamoxifen carries a small increased risk of endometrial cancer and thromboembolic events — against the estimated absolute risk reduction for each individual.

Risk-Reduction Surgery

Risk-reducing bilateral mastectomy (RRBM) reduces the risk of breast cancer by approximately 90–95% in BRCA carriers. Risk-reducing salpingo-oophorectomy (RRSO) reduces ovarian cancer risk by approximately 80–96% and, when performed before natural menopause, also reduces breast cancer risk in BRCA1 carriers by approximately 50%. Timing is critical: guidelines generally recommend RRSO between ages 35 and 40 for BRCA1 carriers (given earlier ovarian cancer onset) and between 40 and 45 for BRCA2 carriers, ideally after completion of childbearing. RRSO carries consequences including surgical menopause, with associated bone density loss, cardiovascular effects, and quality-of-life changes that require proactive management.

Treatment Implications for Those Already Diagnosed

PARP Inhibitors: Exploiting the DNA Repair Defect

If you receive a BRCA-positive result in the context of an existing cancer diagnosis, it is not only prognostic — it is directly therapeutic. BRCA-mutated tumours are exquisitely sensitive to PARP inhibitors (PARPi), a drug class that blocks the PARP enzyme responsible for repairing single-strand DNA breaks. In HR-deficient cells, blocking PARP leads to the accumulation of single-strand breaks that collapse into double-strand breaks during replication, which cannot be repaired — causing cell death. This mechanism, called synthetic lethality, selectively kills BRCA-mutated tumour cells while leaving HR-proficient normal cells largely unharmed.

Approved PARP inhibitors in this setting include olaparib and talazoparib for HER2-negative BRCA-mutated breast cancer, and olaparib, niraparib, and rucaparib for BRCA-mutated ovarian cancer. Response rates in this population are substantially higher than with standard chemotherapy, and progression-free survival benefits have been demonstrated in multiple phase III trials. The development of PARPi resistance — through restoration of HR function via secondary mutations — is an active research area with emerging strategies to overcome it. Understanding the molecular basis of your specific tumour through precision oncology tumour profiling can help predict and manage resistance patterns.

Family Testing and Cascade Screening

Who in Your Family Should Be Tested

A BRCA pathogenic variant has direct implications for first-degree relatives — parents, siblings, and children — each of whom has a 50% probability of carrying the same variant. Second-degree relatives (aunts, uncles, grandparents, grandchildren) have a 25% prior probability. Cascade testing — systematically offering testing to at-risk relatives starting with the closest — is one of the highest-value interventions in cancer genetics, as it identifies carriers before cancer develops, when preventive options are most effective. Genetic counselling services can provide relatives with a personalised letter explaining the family variant and how to access testing through their own healthcare provider.

Male carriers of BRCA2 face a lifetime breast cancer risk of approximately 7–8% — roughly 80 times higher than the general male population — and a significantly elevated prostate cancer risk. Male BRCA1 carriers face a 1–2% lifetime breast cancer risk and a moderately elevated prostate cancer risk. Male carriers should not be overlooked in cascade testing programmes and should be enrolled in appropriate surveillance protocols.

Insurance and Legal Protections

In the United States, the Genetic Information Nondiscrimination Act (GINA) prohibits health insurers and employers from discriminating based on genetic information. However, GINA does not cover life insurance, disability insurance, or long-term care insurance — areas where genetic test results can potentially be used to deny coverage or increase premiums. In the UK, the Association of British Insurers maintains a voluntary moratorium on using predictive genetic test results for most policies. Understanding these legal landscapes before testing is an important part of the informed consent process, and a genetic counsellor can discuss the practical implications for your specific situation and jurisdiction.

The Role of Precision Medicine and AI in BRCA Management

Beyond Binary Results: Polygenic Risk and Multi-Gene Panels

BRCA testing has evolved from single-gene sequencing to multi-gene hereditary cancer panels that simultaneously assess dozens of clinically relevant genes. Moderate-risk genes — PALB2, CHEK2, ATM, RAD51C, RAD51D — are now routinely included and can substantially alter management for individuals who test negative for BRCA1/2 but positive for these additional genes. Furthermore, polygenic risk scores (PRS), which aggregate the small effects of hundreds of common variants, are beginning to be integrated with single-gene results to generate a composite risk estimate that is more accurate than either approach alone. This represents the frontier of precision medicine applied to hereditary cancer risk.

AI and machine learning are accelerating the reclassification of variants of uncertain significance by integrating functional assay data, evolutionary conservation scores, protein structural modelling, and large-scale epidemiological data from biobanks. Models trained on millions of variant-phenotype associations can now predict pathogenicity for many VUS with accuracy approaching that of expert panel classification. As these tools mature, the proportion of results that fall into the uncertain category is expected to decline significantly, giving clinicians and patients more actionable information from the same sequencing data — a central promise of pharmacogenomics and genomic precision.

Building Your Clinical Team

Navigating a positive BRCA result is not a solo endeavour. An optimal team includes a certified genetic counsellor who can contextualise your result within your family history and explain cascade testing; a high-risk breast specialist or surgical oncologist who can guide surveillance and risk-reduction options; a gynaecologic oncologist if ovarian risk management is relevant; a mental health professional experienced in hereditary cancer, given the documented psychological burden of genetic testing; and, if cancer is already present, a medical oncologist familiar with BRCA-targeted therapies. Many major cancer centres now host dedicated hereditary cancer programmes where this expertise is co-located, reducing the coordination burden on patients.

Practical Next Steps After Receiving Your Result

Immediately After a Positive Result

The first practical step after receiving a pathogenic or likely pathogenic result is to schedule a post-disclosure appointment with a genetic counsellor if one was not present at result disclosure. Many patients receive results through direct-to-consumer testing or primary care without adequate genetic expertise — in these situations, prompt referral to a specialist genetics service is essential before any management decisions are made. Bring your full test report, including the specific variant identified (e.g., BRCA1 c.5266dupC, commonly called 5382insC), as the exact variant matters for family cascade testing and is relevant to risk estimation.

Request that your medical records reflect your BRCA status clearly, so that any future healthcare provider — emergency physician, anaesthetist, or specialist — has access to this information. Understanding how to access and manage your medical records is a practical skill that becomes particularly important when coordinating care across multiple specialties.

Living as a Carrier: The Psychological Dimension

Research consistently shows that the majority of BRCA carriers adapt well psychologically over time, particularly those who take active steps toward risk management. Initial distress is normal and expected — a systematic review found that anxiety and cancer-specific distress are elevated in the first weeks after a positive result but return toward baseline in most individuals within six to twelve months. What predicts better psychological outcomes is not the result itself but the quality of information received, the support available, and the ability to act on the information. Support groups — both in-person and online — run by organisations such as FORCE (Facing Our Risk of Cancer Empowered) provide peer connection that clinical teams cannot replicate.